Insulet Corporation (PODD) Q1 2025 10-Q Quarterly Report
Filed: May 9, 2025Period ending Mar 31, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR Insulet Corporation (PODD) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 9, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Insulet Corporation Q1 2025 10-Q Analysis
Risk Factors
- • Continued supply chain disruptions impacting production capacity and inventory levels
- • Exposure to competitive threats from new insulin delivery technologies
Insulet Corporation Q1 2025 Quarterly FinancialsXBRL
Revenue
$569M
▲ +28.8% YoY
Net Income
$35M
▼ -31.3% YoY
Gross Margin
71.9%
▲ +242bp YoY
Operating Margin
15.6%
▲ +272bp YoY
Net Margin
6.2%
▼ -544bp YoY
EPS (Diluted)
$0.50
▼ -31.5% YoY
Operating Cash Flow
$64M
▼ -27.2% YoY
Source: XBRL data from Insulet Corporation Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Insulet Corporation Quarterly Reports
Get deeper insights on Insulet Corporation
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.